Academic Journals Database
Disseminating quality controlled scientific knowledge

Concurrent Hypofractionated Three-dimensional Re-irradiation and Temozolomide in Recurrent Malignant Glioma

ADD TO MY LIST
 
Author(s): Doaa Ali Sharaf Eldeen | Eman Abd Elkareem Toson | Maiy Abd Elraheem Alshahat | Ahmed Nageeb Taha

Journal: Middle East Journal of Cancer
ISSN 2008-6709

Volume: 3;
Issue: 2 ;
Start page: 65;
Date: 2012;
Original page

Keywords: Recurrent malignant glioma | Hypofractionated re-irradiation | Temozolomide

ABSTRACT
Background: This study determines the efficacy and tolerability of hypofractionated three-dimensional conformal radiotherapy in conjunction with daily temozolomide in treatment of previously irradiated recurrent malignant glioma.Methods: We enrolled 21 patients diagnosed with recurrent or progressive malignant glioma who previously underwent external beam irradiation. All patients had hypofractionated three-dimensional conformal radiotherapy to a total dose of 30 Gy in six fractions, over a two-week period, concurrent with daily temozolomide (75 mg/m2).Results: At the median follow up of 9.5 months (range: 2.5-42), there were 18 (86%) patients who had died. Median overall survival from the onset of hypofractionated threedimensional conformal radiotherapy was nine months and median time to progression was five months. There was no detectable severe toxicity. Salvage surgery prior to hypofractionated three-dimensional conformal radiotherapy and planning target volume significantly influenced patient outcome according to multivariate analysis.Conclusion: Hypofractionated conformal re-irradiation concurrent with daily temozolomide is a feasible, well-tolerated treatment for recurrent malignant glioma. Patients with surgical re-resection and smaller planning target volumes have the most favorable outcomes.
RPA Switzerland

RPA Switzerland

Robotic process automation

    

Tango Rapperswil
Tango Rapperswil